Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | HNF4A | P41235 | 3/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL27448159 | 0.96 | KDM4E (0.51) | KDM4ELMNASMN1; SMN2POLBALOX15 | |
| SCHEMBL7729548 | 0.89 | KDM4E (0.50) | KDM4ELMNASMN1; SMN2POLBALOX15 | |
| SCHEMBL27717172 | 0.88 | ACMSD (0.50) | KDM4ELMNAKDM4AKDM5AKDM4C | |
| SCHEMBL8189644 | 0.88 | CDC25B (0.49) | KDM4ELMNASMN1; SMN2POLBALOX15 | |
| SCHEMBL1729990 | 0.87 | DHODH (0.49) | KDM4ELMNAMCL1 | |
| SCHEMBL7666259 | 0.85 | KDM4E (0.47) | KDM4ELMNASMN1; SMN2ALOX15ALDH1A1 | |
| SCHEMBL11957361 | 0.85 | SMN1; SMN2 (0.49) | KDM4ELMNASMN1; SMN2ALOX15ALDH1A1 | |
| SCHEMBL27579261 | 0.85 | TPMT (0.43) | KDM4ELMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL9519620 | 0.84 | CA12 (0.45) | KDM4ELMNASMN1; SMN2ALOX15ALDH1A1 | |
| SCHEMBL16974002 | 0.84 | SMN1; SMN2 (0.46) | KDM4ELMNASMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820867-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-05-19 | — | — | EP | disclosed |
| EP-3774737-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Blade Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111592529-A | Phenyl pyrazole amide derivative and preparation method and application thereof | 安阳师范学院 | 2020-08-28 | — | — | CN | disclosed |
| WO-2020012427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-01-16 | — | — | WO | disclosed |
| WO-2019190885-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| CN-107903251-A | Pyrazole formylamine derivate as the TAAR conditioning agents for treating several conditions such as depression, diabetes and Parkinson's | 霍夫曼-拉罗奇有限公司 | 2018-04-13 | — | — | CN | disclosed |
| CN-103649053-B | Aminomethyl quinolone compounds | 霍夫曼-拉罗奇有限公司 | 2017-07-04 | — | — | CN | disclosed |
| EP-2410858-B1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8946231-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| CN-103649053-A | Aminomethyl quinolone compounds | HOFFMANN LA ROCHE | 2014-03-19 | — | — | CN | disclosed |
| CN-102659774-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE | 2012-09-12 | — | — | CN | disclosed |
| EP-2410858-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | disclosed |
| WO-2010111059-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| EP-0540614-A1 | 3-(1-SUBSTITUTEDPYRAZOYL)-2-OXINDOLE DERIVATIVES. | PFIZER (US) | 1993-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | KDM4E 1395/4885LMNA 1819/4885SMN1; SMN2 4686/4885 |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | KDM4E 3919/4885LMNA 4001/4885SMN1; SMN2 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.